These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 37391394)

  • 1. SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors.
    Yang Y; Xu G
    Cell Death Dis; 2023 Jun; 14(6):390. PubMed ID: 37391394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan.
    Sato T; Kodama S; Kaneko K; Imai J; Katagiri H
    Emerg Infect Dis; 2022 Jul; 28(7):1518-1520. PubMed ID: 35468049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review.
    Spagnolo F; Boutros A; Croce E; Cecchi F; Arecco L; Tanda E; Pronzato P; Lambertini M
    Eur J Clin Invest; 2021 Jul; 51(7):e13604. PubMed ID: 34021591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
    Ruiz JI; Lopez-Olivo MA; Geng Y; Suarez-Almazor ME
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36746512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study.
    Mandala M; Lorigan P; De Luca M; Bianchetti A; Merelli B; Bettini AC; Bonomi L; Nahm S; Vitale MG; Negrini G; Di Croce A; Ascierto PA; Rulli E; Tondini CA
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological response and immune-related adverse events following COVID-19 vaccination in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Wang Y; Chen D; Pan Y; Li H; Zhao W; Lu T; Kong W; Ding M; Wang X; Zhang G
    Rev Med Virol; 2024 Jan; 34(1):e2495. PubMed ID: 38017632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.
    Luo B; Li J; Hou X; Yang Q; Zhou Y; Ye J; Wu X; Feng Y; Hu T; Xu Z; He Y; Sun J
    Future Oncol; 2021 Sep; 17(26):3477-3484. PubMed ID: 34189948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan.
    Hibino M; Uryu K; Takeda T; Kunimatsu Y; Shiotsu S; Uchino J; Hirai S; Yamada T; Okada A; Hasegawa Y; Hiranuma O; Chihara Y; Kamada R; Tobe S; Maeda K; Horiuchi S; Kondo T; Takayama K
    J Thorac Oncol; 2022 Aug; 17(8):1002-1013. PubMed ID: 35752437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of immune checkpoint inhibitors with SARS-CoV-2 infection rate and prognosis in patients with solid tumors: a systematic review and meta-analysis.
    Sun L; Zhao F; Xiang Y; Chen S; Shu Q
    Front Immunol; 2024; 15():1259112. PubMed ID: 38887296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination.
    Janzic U; Bidovec-Stojkovic U; Mohorcic K; Mrak L; Dovnik NF; Ivanovic M; Ravnik M; Caks M; Skof E; Debeljak J; Korosec P; Rijavec M
    Future Oncol; 2022 Jul; 18(23):2537-2550. PubMed ID: 35678621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune responses to SARS-CoV-2 in vaccinated patients receiving checkpoint blockade immunotherapy for cancer.
    Piening A; Ebert E; Khojandi N; Alspach E; Teague RM
    Front Immunol; 2022; 13():1022732. PubMed ID: 36582225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade.
    Niewolik J; Mikuteit M; Cossmann A; Vahldiek K; Gutzmer R; Müller F; Schröder D; Heinemann S; Behrens GMN; Dopfer-Jablonka A; Steffens S; Grimmelmann I
    Oncology; 2022; 100(7):392-398. PubMed ID: 35609553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study.
    Tamura T; Ninomiya K; Kubo T; Kuyama S; Tachibana S; Inoue K; Chikamori K; Kudo K; Ochi N; Harada D; Maeda Y; Kiura K
    Thorac Cancer; 2022 Feb; 13(3):453-459. PubMed ID: 34964270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET).
    Body A; Ahern E; Lal L; Gillett K; Abdulla H; Opat S; O'Brien T; Downie P; Turville S; Munier CML; Smith C; MacIntyre CR; Segelov E
    BMC Infect Dis; 2022 Jan; 22(1):70. PubMed ID: 35057745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.
    Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ
    Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report.
    Lasagna A; Lenti MV; Cassaniti I; Sacchi P
    Immunotherapy; 2022 Aug; 14(12):915-925. PubMed ID: 35694999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study.
    Lasagna A; Agustoni F; Percivalle E; Borgetto S; Paulet A; Comolli G; Sarasini A; Bergami F; Sammartino JC; Ferrari A; Zavaglio F; Arena F; Lilleri D; Secondino S; Falzoni M; Schiavo R; Klersy C; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2021 Oct; 6(5):100272. PubMed ID: 34543863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.